Novelty Nobility Inc. is a South Korean biotechnology company focused on the development of bispecific antibody therapeutics. Its lead candidate, NN4101, targets retinal neovascular diseases and is being advanced in collaboration with AGC Biologics. The partnership encompasses cell-line development, master cell bank creation, process optimization, and GMP manufacturing across facilities in Denmark, Japan, the United States, and Europe.
Official website: noveltynobility.com
